Journals / Turkish Journal of Gastroenterology / 2006 / Cilt: 17 - Sayı: 3

Atrofik gastritte serolojik bir gösterge olarak serum pepsinojenleri ile Helicobacter pylori arasındaki ilişki

Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis

Pages
172–176
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Additionally, the usage of pepsinogen II as a serum marker in predicting the eradication of H. pylori with atrophic gastritis could be more reliable than pepsinogen I or the I/II ratio.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Serum pepsinogen levels are considered as a non-endoscopic blood test in the diagnosis of atrophic gastritis.
📊
Key Findings & Data:Methods: The study enrolled a total of 30 cases with atrophic gastritis (18 H. pylori-positive and 12 H. pylori-negative).
💡
Conclusion & Impact:Additionally, the usage of pepsinogen II as a serum marker in predicting the eradication of H. pylori with atrophic gastritis could be more reliable than pepsinogen I or the I/II ratio.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Gastrit · atrofik · Testlerin kestirim değeri

Abstract

Background/aims: Serum pepsinogen levels are considered as a non-endoscopic blood test in the diagnosis of atrophic gastritis. The objective of the present study was to investigate whether there is any difference between pepsinogen levels in Helicobacter pylori-positive and -negative patients with atrophic gastritis, and to analyze the relationship between histopathology and pepsinogen levels after treatment in H. pylori-positive patients with atrophic gastritis. Methods: The study enrolled a total of 30 cases with atrophic gastritis (18 H. pylori-positive and 12 H. pylori-negative). The H. pylori-positive cases received a one-week eradication treatment. Initially for all and after the treatment for H. pylori-positive cases, serum pepsinogen I and II levels, anti-H. pylori IgG titration and histopathologic analysis were carried out. Results: In the H. pylori-positive patients with atrophic gastritis, the levels of pepsinogen I and pepsinogen I/II ratio were lower while the levels of pepsinogen II were higher compared to the H. pylori-negative patients (p<0.05 for all). The post-treatment serum pepsinogen I levels and pepsinogen I/II ratios did not change in the H. pylori-positive group, while the levels of pepsinogen II, H. pylori antibody titration and gastric atrophy degree remarkably decreased (p<0.05 for all). Conclusions: In atrophic gastritis, the levels of serum pepsinogen and pepsinogen I/II ratio show a difference in H. pylori-negative versus &#8211;positive cases. Additionally, the usage of pepsinogen II as a serum marker in predicting the eradication of H. pylori with atrophic gastritis could be more reliable than pepsinogen I or the I/II ratio.

Özet

Serum pepsinogen düzeyleri atrofik gastrit tanısında non-endoskopik bir kan testi olarak kabul edilmektedir. Bu çalışmada Helicobacter pylori pozitif ve negatif atrofik gastritlilerde pepsinojen düzeylerinde fark olup olmadığını ve Heliko-bacter pylori pozitif atrofik gastritlilerde tedavi sonrası histo-patoloji ile pepsinojen düzeyleri arasındaki ilişkiyi incelemek amaçlanmıştır. Yöntem: On sekizi Helicobacter pylori pozitif ve 12'si negatif toplam 30 atrofik gastritli olgu çalışmaya alındı. Helicobacter pylori pozitif olgular 1 haftalık eradikasyon tedavisi aldılar. İnisyal tüm olgularda ve Helicobacter pylori pozitiflerde tedavi sonu G.ayda serum pepsinojen I ve II düzeyi, anti- Helicobacter pylori IgG titrasyonu ve endoskopik biopsi-lerde histopatolojik inceleme yapıldı. Bulgular: Helicobacter pylori pozitif atrofik gastritlilerde pepsinojen I düzeyleri ve pepsinojen I/II oranı Helicobacter pylori negatiflere göre daha düşük iken serum pepsinojen II düzeyleri daha yüksekti (p<0.05, tümü için). Helicobacter pylori pozitiflerde tedavi sonrası serum pepsinojen I düzeyleri ve 11II oranları değişmediği halde serum pepsinojen II düzeyleri, Helicobacter pylori antikor titrasyonları ve atrofik gastrit düzeyleri belirgin olarak azaldı (p<0.05, tümü için). Sonuç: Atrofik gastritte, serum pepsinojen düzeyleri ve pepsinojen IIII oranı Helicobacter pylori negatiflerde pozitiflerden farklıdır. Ek olarak, atrofik gastritlilerde helicobacter pylori eradikasyonunu belirlemede bir serum göstergesi olarak pepsinjen II düzeylerinin kullanımı pepsinojen I ve pepsinojen 11II oranına göre daha uygun olabilir.

🔖

Cite This Article

BÖLÜKBAŞ, C., BÖLÜKBAŞ, F. F., ÖVÜNÇ, O., KILIÇ, G., DALAY, R., GÜVEN, H., URAS, F., YARDIMCI, T. K., SÖKMEN, M. H., AGAN, A. F., PİŞKİNPAŞA, N. (2006). Atrofik gastritte serolojik bir gösterge olarak serum pepsinojenleri ile Helicobacter pylori arasındaki ilişki. Turkish Journal of Gastroenterology, Cilt: 17 - Sayı: 3, 172–176. https://ajindex.com/articles/410360

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kuipers EJ. In through the out door: serology for atrophic gastritis. Eur J Gastroenterol Hepatol 2003; 15: 877-9
  2. Lewin KJ, Warren JR. Unidentified curved bacillus on gastric epithelium in active chronic gastritis. Lancet 1984; 1: 1273-5
  3. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19: 37-43
  4. Varis O, Vale J, Siurala M. Is Helicobacter pylori involved in pathogenesis of the gastritis characteristic of pernicious anemia? Comparison between pernicious anemia relatives and duodenal ulcer relatives. Scand J Gastroenterol 1993; 28: 705-8
  5. Kawaguchi H, Haruma K, Komoto K, et al. Helicobacter pylori infection is the major risk factor for atrophic gastritis. Am J Gastroenterol 1996; 91: 959-62
  6. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525-8
  7. Tucci A, Biasco G, Paparo GF. Effect of eradication of Helicobacter pylori in patient with fundic atrophic gastritis. N Engl J Med 1997; 336: 957-8
  8. Borody TJ, Andrews P, Jankiewicz E, et al. Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori. Am J Gastroenterol 1993; 88: 1266-8
  9. Hersey SJ. Gastric secretion of pepsins. In: Johnson LR, ed. Physiology of the Gastrointestinal Tract. 3rd ed. New York: Raven Press, 1994; 1227-40
  10. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102: 760-6
  11. Samloff IM, Varis K, Ihamaki T, et al. Relationships among serum pepsinogen I, serum pepsinogen II and gastric mucosal history. A study in relatives of patients with pernicious anemia. Gastroenterology 1982; 83: 204-9
  12. Samloff IM. Pepsinogens I and II: purification from gastric mucosa and radioimmunoassay in serum. Gastroenterology 1982; 82: 26-33
  13. Hunter FM, Correa P, Fontham E, et al. Serum pepsinogens as markers of response to therapy for Helicobacter pylori. Dig Dis Sci 1993; 38: 2081-6
  14. Mihara M, Haruma K, Kamada T, et al. Eradication of Helicobacter pylori (Hp) normalizes the circumstance in the stomach for 6 months follow (Abstract). In: Xth International Workshop on gastroduodenal pathology and Helicobacter pylori. Lisbon, Portugal, 1997; 12-14
  15. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J